The reduction in tumor-specific expression of HIF-1α across the cisplatin, bevacizumab + metformin, bevacizumab + cisplatin, and metformin + cisplatin groups were not statistically significant compared with the control (Figure 5E). This evidence concerns the gene HIF1A and neoplasm.